Stri

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Monday, October 31, 2022
Escape Room, RNA transfection, EIF4E, Therapy, Survival, Stri, MNK, Pfizer, Pembrolizumab, KRAS, Cancer, 4F, GLOBE, STRI, COVID-19, University of California, San Francisco, ER, University, NASDAQ, Investor, Protein, Patient, San Francisco, SAN, DARPA, NSCLC, EIF4A, Pharmaceutical industry, KICKSTART

A replay of the webcasts will be available for 30 days following the event.

Key Points: 
  • A replay of the webcasts will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics to Present at Cantor Oncology, Hematology, HemeOnc Conference

Retrieved on: 
Wednesday, September 21, 2022
EIF4E, Stri, COVID-19, University of California, San Francisco, Effector, RNA transfection, EIF4A, NSCLC, DARPA, 4F, Survival, STRI, Patient, ER, Cancer, Protein, San Francisco, KRAS, Escape Room, Pembrolizumab, University, MNK, Pfizer, Pharmaceutical industry, Vaccine, KICKSTART

eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

Key Points: 
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • Zotatifin, eFFECTORs inhibitor of eIF4A, is currently being evaluated in Phase 2a expansion cohorts in certain biomarker-positive solid tumors, including ER+ breast cancer and KRAS-mutant NSCLC.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022
University, COVID-19, San Francisco, Cancer, Survival, STRI, Pfizer, Protein, Stri, DARPA, University of California, San Francisco, EIF4E, 4F, Pembrolizumab, KRAS, NSCLC, ER, Investor, Webcast, RNA transfection, MNK, EIF4A, Patient, Escape Room, Online shopping, Pharmaceutical industry, KICKSTART

A replay of the webcast will be available for 30 days following the event.

Key Points: 
  • A replay of the webcast will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics to Present at JMP Securities Life Sciences Conference

Retrieved on: 
Tuesday, June 7, 2022
Company, Conference, ER, Survival, JMP, University of California, San Francisco, DARPA, EIF4A, ET, MNK, 4F, Pfizer, Investor, University, Pembrolizumab, STRI, Therapy, GLOBE, Patient, RNA transfection, San Francisco, COVID-19, NASDAQ, SAN, Escape Room, EIF4E, NSCLC, KRAS, Stri, Cancer, Protein, Pharmaceutical industry, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.

Key Points: 
  • SAN DIEGO and REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that the Company will present and host 1x1 meetings at JMP Securities Life Sciences Conference.
  • The eFFECTOR Team is scheduled to hold a fireside chat on June 15th at 10:30 am ET and will host investor meeting at the conference through June 16th.
  • A live webcast will be available on the "Events and Presentation" page of the Investors section of the Companys website.
  • eFFECTOR is a clinical-stage biopharmaceutical company pioneering the development of a new class of oncology drugs referred to as STRIs.

eFFECTOR Therapeutics Announces Transition in Clinical Leadership

Retrieved on: 
Monday, April 4, 2022
Journal, Therapy, American Medical Association, Effector, Johns Hopkins School of Medicine, NASDAQ, Patient, EIF4E, KRAS, Massachusetts General Hospital, Survival, Biotechnology, Hospital, ER, Cancer, MedImmune, Science, NSCLC, Pfizer, Knowledge, EIF4A, RNA transfection, Stri, GLOBE, MNK, 4F, STRI, SAN, FDA, Protein, Escape Room, JAMA, Pembrolizumab, Amgen, Pharmaceutical industry, KICKSTART

SAN DIEGO and REDWOOD CITY, Calif., April 04, 2022 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics, Inc. (NASDAQ: EFTR), a biopharmaceutical company pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that its chief medical officer Premal Patel, M.D., Ph.D., has resigned to pursue a new opportunity. Robert Sikorski, M.D., Ph.D., who currently serves as a clinical advisor to the company, will take on an expanded role as senior clinical development advisor while the company conducts an executive search for a new chief medical officer. Dr. Sikorski, who played a similar role for eFFECTOR in 2020, has a deep knowledge of the company’s STRI development programs and will lead clinical development of both tomivosertib and zotatifin. In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022.

Key Points: 
  • Dr. Sikorski, who played a similar role for eFFECTOR in 2020, has a deep knowledge of the companys STRI development programs and will lead clinical development of both tomivosertib and zotatifin.
  • In addition, Dr. Patel will serve as a consultant to eFFECTOR through September 30, 2022.
  • Before joining Medimmune, he led late-stage clinical development and post marketing efforts for several commercial drugs and drug candidates at Amgen.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Appoints Kristen Harrington-Smith to Board of Directors

Retrieved on: 
Wednesday, February 16, 2022
Pembrolizumab, NASDAQ, Patient, Cancer, KRAS, Degenerative disease, EIF4A, Stri, MNK, STRI, VP, SAN, RNA transfection, UNC Kenan–Flagler Business School, Chapel Hill, Leadership, GLOBE, Therapy, Escape Room, Gene therapy, Hematology, M.B.A, EIF4E, Protein, Williams College, ER, University of North Carolina at Greensboro, Pfizer, Psychology, Survival, San Francisco, Senior, NSCLC, ImmunoGen, Growth, COVID-19, University, University of California, San Francisco, Novartis, Industry, 4F, Effector, Management, Pharmaceutical industry, KICKSTART

Concurrent with Ms. Harrington-Smiths appointment, Jonathan Root, M.D., has resigned from the companys board of directors.

Key Points: 
  • Concurrent with Ms. Harrington-Smiths appointment, Jonathan Root, M.D., has resigned from the companys board of directors.
  • Kristen is an exceptional strategic thinker with a track record of success launching novel products in oncology, said Steve Worland, President and Chief Executive Officer of eFFECTOR.
  • Dr. Root added, eFFECTOR has made great progress over the years and I am proud to have served on its board since the formation of the company.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics to Participate in The JMP Securities Hematology and Oncology Summit

Retrieved on: 
Monday, November 22, 2021
Patient, NSCLC, University of California, San Francisco, DARPA, Protein, ER, 4F, Stri, EIF4A, Cancer, Pfizer, SAN, University, Investor, COVID-19, Hematology, Effector, MNK, Escape Room, Pembrolizumab, Survival, GLOBE, STRI, RNA transfection, EIF4E, Webcast, Therapy, San Francisco, NASDAQ, KRAS, Pharmaceutical industry

SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday, December 6 at 3:20 p.m.

Key Points: 
  • SAN DIEGO, Nov. 22, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a biopharmaceutical company focused on pioneering the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that Steve Worland, Ph.D., President and Chief Executive Officer of eFFECTOR, will participate in a fireside chat at the JMP Securities Hematology and Oncology Summit on Monday, December 6 at 3:20 p.m.
  • A live webcast of the event will be available on the "Events and Presentation" page of the Investors section of the Companys website.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics to Participate in Upcoming Investor Conferences

Retrieved on: 
Tuesday, October 26, 2021
University of California, San Francisco, RNA transfection, NSCLC, SAN, University, Cancer, Survival, STRI, 4F, Pfizer, Patient, NASDAQ, Investor, San Francisco, Fireside chats, Stifel, Conference, EIF4E, Protein, Stri, COVID-19, Credit, ER, Escape Room, Therapy, EIF4A, GLOBE, Pembrolizumab, DARPA, MNK, KRAS, Pharmaceutical industry

A replay of the webcasts will be available for 30 days following the event.

Key Points: 
  • A replay of the webcasts will be available for 30 days following the event.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

Baylor College of Medicine to Present eFFECTOR Therapeutics-Supported Research at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, September 30, 2021
STRI, Therapy, University of California, San Francisco, RNA transfection, Molecular biology, Research, Time, American Association, Protein, Symposium, National Postdoctoral Association, Conference, NASDAQ, Patient, Molecule, AACR, ER, Baylor College of Medicine, Treatment, San Francisco, NSCLC, 4F, University, American Association for Cancer Research, EIF4A, MNK, SAN, Medicine, National Cancer Institute, EIF4E, COVID-19, Pfizer, EORTC, Drug development, European Organization for Quality, DARPA, Survival, National, NCI, KRAS, Escape Room, Pembrolizumab, Stri, GLOBE, Department, Pharmaceutical industry

ET October 10 at 5:45 pm ET

Key Points: 
  • ET October 10 at 5:45 pm ET
    Hosted by the European Organization for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR), the 2021 Molecular Targets and Cancer Therapeutics conference will take place as a virtual eventOctober 7-10, 2021.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.
  • eFFECTORs STRI product candidates target the eIF4F complex and its activating kinase, mitogen-activated protein kinase interacting kinase (MNK).
  • eFFECTOR has a global collaboration with Pfizer to develop inhibitors of a third target, eIF4E.

eFFECTOR Therapeutics to Participate in 2021 Cantor Virtual Healthcare Conference

Retrieved on: 
Thursday, September 16, 2021
Pfizer, MNK, Therapy, SAN, STRI, EIF4A, University, Investor, Conference, Stri, Protein, Patient, EIF4E, Pembrolizumab, Survival, NASDAQ, 4F, DARPA, COVID-19, KRAS, ER, NSCLC, Escape Room, Webcast, San Francisco, GLOBE, RNA transfection, University of California, San Francisco, Cancer, Pharmaceutical industry

SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m.

Key Points: 
  • SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- eFFECTOR Therapeutics (NASDAQ: EFTR), a leader in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer, today announced that company management will participate in a fireside chat at the 2021 Cantor Virtual Global Healthcare Conference at 2:40 p.m.
  • ET on Tuesday, September 28, 2021. eFFECTOR will also host investor meetings throughout the conference.
  • A live webcast of the fireside chat will be available on the "Events and Presentation" page of the Investors section of the Companys website.
  • eFFECTOR is a clinical-stage biopharmaceutical company focused on pioneering the development of a new class of oncology drugs referred to as STRIs.